Zacks Investment Research
13 Jul 2026, 22:51 UTC · 1h ago
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
13 Jul 2026, 22:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Adma Biologics' full-year earnings per share are projected to increase by 36.67% compared to the previous year. — Strong double-digit growth projections for annual earnings typically drive positive investor sentiment and share price appreciation.
+0.40Adma Biologics is currently trading at a Forward P/E ratio of 11.07, significantly lower than its industry average of 20.52. — A significant valuation discount relative to peers suggests the stock may be undervalued, providing an attractive entry point for value investors.
+0.30Adma Biologics' shares increased 10.6% over the last month, outperforming both the Medical sector and the S&P 500. — Strong relative momentum indicates positive market reception, though it is a lagging indicator rather than a forward-looking catalyst.
+0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Adma Biologics has a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates a neutral outlook, suggesting no immediate strong catalyst for a directional price move.
+0.00Which stocks this story touches
The company shows positive projected EPS and revenue growth and has outperformed the S&P 500 over the last month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
